Articles From: Merck to Present Updated Interim Data from Phase II Trial Evaluating Investigational NS3/4A Protease Inhibitor MK-5172 for Chronic Hepatitis C Virus Genotype 1 Infection at the International Liver Congress™ to Home Bancorp Announces 2013 First Quarter Results


2013/4/23
Merck (NYSE: MRK) , known as MSD outside the United States and Canada, today announced the presentation of the latest interim data from a Phase II, multi-center, randomized, dose-ranging clinical trial evaluating the safety and antiviral activity of MK-5172, for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection.
Sign-up for Merck to Present Updated Interim Data from Phase II Trial Evaluating Investigational NS3/4A Protease Inhibitor MK-5172 for Chronic Hepatitis C Virus Genotype 1 Infection at the International Liver Congress™ investment picks
2013/4/23
JOHANNESBURG-BP Group (BP) Tuesday said the energy company will invest more than 5 billion rand ( $540 million ) in South Africa and Mozambique over the next five years.
Sign-up for BP to Invest 5Bln Rand in S Africa, Mozambique in Next 5 Years investment picks
2013/4/23
Integrated Device Technology, Inc. ( IDT ® ) (NASDAQ: IDTI) , the Analog and Digital Company™ delivering essential mixed-signal semiconductor solutions, today announced the industry’s first Glitch-Free™ radio frequency (RF) digital step attenuator (DSA) with integrated blocking capacitors.
Sign-up for IDT Announces Industry’s First Glitch-Free™ RF Digital Step Attenuator with Integrated Blocking Capacitors investment picks
2013/4/23
CAMBRIDGE, Mass.
Sign-up for Akamai Releases Fourth Quarter 2012 'State of the Internet' Report investment picks
2013/4/23
AUSTIN, Texas, April 23, 2013 (GLOBE NEWSWIRE) -- Superconductor Technologies Inc. (STI) (Nasdaq:SCON) , a world leader in the development and production of high temperature superconducting (HTS) materials and associated technologies, announces that it has recently received purchase orders from multiple customers for its Conductus ® 2G HTS wire.
Sign-up for Superconductor Technologies Announces the Receipt of Purchase Orders From Leading Multinational Industrial Companies for Conductus 2G HTS Wire investment picks
2013/4/23
TAIPEI, Taiwan, April 23, 2013 (GLOBE NEWSWIRE) -- Silicon Motion Technology Corporation (Nasdaq:SIMO) ("Silicon Motion" or the "Company"), a global leader in designing and marketing NAND flash controllers for solid state storage devices and specialty RF IC solutions for mobile devices, announces today its next quarterly cash dividend.
Sign-up for Silicon Motion Announces Quarterly Dividend investment picks
2013/4/23
CIT Group Inc. (NYSE: CIT) , a leading provider of financing and advisory services to small businesses and middle market companies, today reported net income of $163 million, $0.81 per diluted share, for the first quarter of 2013, compared to a net loss of $427 million, ($2.13) per diluted share, for the first quarter of 2012.
Sign-up for CIT Reports First Quarter 2013 Net Income of $163 Million ($0.81 Per Diluted Share) investment picks
2013/4/23
Veris Gold Corp.
Sign-up for Veris Gold Corp. Announces New Team Members investment picks
2013/4/23
Toronto Stock Exchange: VG VANCOUVER , April 23, 2013 /PRNewswire/ - Veris Gold Corp.
Sign-up for Veris Gold Corp. Announces New Team Members investment picks
2013/4/23
Continues Development of Harvester Project for Monitoring Radiation in the Atmosphere CALABASAS, Calif.
Sign-up for National Technical Systems Wins New Contract from Sandia National Laboratories investment picks
2013/4/23
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that its first quarter 2013 financial results will be released on Tuesday, May 7, 2013.
Sign-up for BioCryst to Announce First Quarter 2013 Financial Results May 7 investment picks
2013/4/23
FRANKFURT --The following is a summary of analysts' forecasts for AstraZeneca plc (AZN) first-quarter results, based on a poll of seven analysts conducted by Dow Jones Newswires (figures in million dollars, EPS and dividend in dollar, target price in pence, according to IFRS). Earnings figures are scheduled to be released April 25 .
Sign-up for EARNINGS FORECAST TABLE: AstraZeneca 1Q 2013 investment picks
2013/4/23
Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA) , a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, announced today that new Phase 2b data related to ABT-450, Enanta’s lead HCV protease inhibitor identified in its ongoing collaboration with AbbVie, as well as new preclinical data on Enanta’s proprietary cyclophilin inhibitor, EDP-546, will be presented at the International Liver Congress, (ILC), which is the 48 th Annual Meeting of the European Association for the Study of the Liver (EASL) taking place in Amsterdam April 24-28, 2013.
Sign-up for Enanta Announces New Data From Phase 2b Interferon-Free Combination Studies with Protease Inhibitor ABT-450 for Hepatitis C Treatment to be Presented at EASL investment picks
2013/4/23
- 96 percent of treatment-naive patients and 93 percent of prior null responders treated with AbbVie's investigational IFN-free, triple-DAA combination therapy achieve SVR24 - Additional analyses looks at response rates in patients with differing baseline factors including gender, viral load and fibrosis stage AMSTERDAM , April 23, 2013 /PRNewswire/ --  (NYSE: ABBV)   – Results from "Aviator,"  AbbVie's phase IIb clinical trial of its investigational direct-acting antivirals (DAAs) for the treatment of hepatitis C virus (HCV) infection, continue to demonstrate high sustained viral response (SVR) rates against genotype 1 HCV, across patient types.
Sign-up for New Data from AbbVie's Phase IIb Aviator Trial Demonstrate High Sustained Viral Response Rates Across Multiple Patient Types with HCV Genotype 1 investment picks
2013/4/23
Investment bank UBS on Tuesday updated its short-term price targets for gold following the precious metal's recent volatility.
Sign-up for UBS Updates Short-Term Gold Price Targets investment picks
2013/4/23
New scholarship program to support the immediate demand for technicians in the transportation industry SCOTTSDALE, Ariz.
Sign-up for Technician Demand Rises, Universal Technical Institute Funds $1 Million Scholarship Program investment picks
2013/4/23
An experimental drug cocktail from Bristol-Myers Squibb Co.
Sign-up for Bristol Says Results of Hepatitis C Drug Trial are Positive investment picks
2013/4/23
JERUSALEM --Israeli online translation company Babylon Ltd.
Sign-up for Israeli Internet Translation Co Babylon Signs Agreement With Yahoo investment picks
2013/4/23
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that detailed results from four Phase 3 clinical trials (NEUTRINO, FISSION, POSITRON and FUSION) evaluating sofosbuvir, the company’s investigational once-daily nucleotide NS5B inhibitor for the treatment of chronic hepatitis C virus (HCV) infection, will be presented this week in oral sessions at the 48th Annual Meeting of the European Association for the Study of the Liver (International Liver Congress 2013) in Amsterdam, The Netherlands.
Sign-up for Data from Phase 3 Studies of Gilead’s Sofosbuvir for Hepatitis C investment picks
2013/4/23
- Phase 1 Results Further Demonstrate Potency of ACH-3102 in Genotypes 1a and 1b and Against Resistant HCV- AMSTERDAM, The Netherlands, April 23, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced the presentation of new data demonstrating the efficacy, safety, tolerability, and combinability of ACH-3102, a second-generation, pan-genotypic NS5A inhibitor, at the 48 th Annual Meeting of the European Association for the Study of the Liver (EASL) during the International Liver Congress 2013.
Sign-up for Achillion Presents New Data on ACH-3102 to Treat Hepatitis C at the International Liver Congress investment picks
2013/4/23
http://media.marketwire.com/attachments/201111/35212_gentex.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1009404&ProfileId=051205&sourceType=1 ZEELAND, MI --
Sign-up for Gentex Announces 1st Quarter 2013 Financial Results Conference Call Webcast investment picks
2013/4/23
InterOil Corporation Announces the Retirement of CEO Phil Mulacek Canada NewsWire PORT MORESBY , Papua New Guinea and HOUSTON , April 23, 2013 /CNW/ - InterOil Corporation (NYSE:IOC) (POMSoX:IOC) ("InterOil") today announced the retirement of its founder and Chief Executive Officer, Phil Mulacek, effective April 30, 2013 .
Sign-up for InterOil Corporation Announces the Retirement of CEO Phil Mulacek investment picks
2013/4/23
High Rates of SVR Demonstrated in Phase II Study with Investigational Triple DAA Regimen of Daclatasvir, Asunaprevir and BMS-791325 in Treatment-Naïve Patients with Genotype 1 Chronic Hepatitis C Infection Canada NewsWire The study results will be presented this week at the International Liver Congress, the 48 th annual meeting of the European Association for the Study of the Liver (EASL), in Amsterdam .
Sign-up for High Rates of SVR Demonstrated in Phase II Study with Investigational Triple DAA Regimen of Daclatasvir, Asunaprevir and BMS-791325 in Treatment-Naïve Patients with Genotype 1 Chronic Hepatitis C Infection investment picks
2013/4/23
Bristol-Myers Squibb Company (NYSE: BMY) today announced additional, interim Phase II data demonstrating that 12- and 24-week Triple DAA treatment regimens of daclatasvir (DCV), asunaprevir (ASV) and BMS-791325 (’325) achieved high rates of sustained virologic response (SVR) of up to 94%, in treatment-naïve, genotype 1 chronic hepatitis C patients, at time points ranging from 4 to 36 weeks post-treatment depending on the treatment group.
Sign-up for High Rates of SVR Demonstrated in Phase II Study with Investigational Triple DAA Regimen of Daclatasvir, Asunaprevir and BMS-791325 in Treatment-Naïve Patients with Genotype 1 Chronic Hepatitis C Infection investment picks
2013/4/23
Polaris Industries Inc. (NYSE: PII) today reported record first quarter net income of $75.5 million, or $1.07 per diluted share, for the quarter ended March 31, 2013.
Sign-up for Polaris Reports Record First Quarter 2013 Results; EPS Increased 26% to $1.07 on 11% Sales Growth investment picks
2013/4/23
--First quarter 2013 net revenue was $470.4 million, an increase of 5.6% from the fourth quarter 2012, and a decrease of (4.4)% from the first quarter 2012.
Sign-up for Sensata Technologies Holding N.V. Announces First Quarter 2013 Results investment picks
2013/4/23
NEW KEY LIME TREATS AND A STAYCATION GIVEAWAY FROM KRISPY KREME WINSTON SALEM, N.C. , April 23, 2013 /PRNewswire/ -- Summer sweetness is now in season with two new sun-kissed and handpicked Key Lime treats from Krispy Kreme®. Key Lime Cake and Key Lime Cheesecake Doughnuts are available April 22 through June 23, 2013 at participating Krispy Kreme US and Canadian locations.
Sign-up for Take Your Tastebuds On A Staycation investment picks
2013/4/23
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0868393001&sourceType=1 http://www.ccnmatthews.com/logos/20110215-bayfield.jpg VANCOUVER, BRITISH COLUMBIA --
Sign-up for Bayfield Drills 11.0m of 12.19 g/t Gold and 30.05 g/t Silver in Rainy River, NW Ontario investment picks
2013/4/23
New LCA methodology delivers first EPD process that allows for the production of labels for every product online, in real-time SAN JOSE, Calif.
Sign-up for Central Concrete Announces First Environmental Product Declarations (EPDs) for Concrete Mixes in the United States investment picks
2013/4/23
LAFAYETTE, La.
Sign-up for Home Bancorp Announces 2013 First Quarter Results investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Morningstar Investing Classroom Rewards (earn as you learn and redeem for Morningstar merchandise)
P   Morningstar Fund Analyst Reports (full research on 2,000 funds and ETFs)
P   Morningstar Stock Analyst Reports (full research on 2,000 stocks)
P   Morningstar Stock and Fund Stewardship Grades
P   Portfolio Manager (advanced with 10 x-ray analyses, including guidance)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Merck to Present Updated Interim Data from Phase II Trial Evaluating Investigational NS3/4A Protease Inhibitor MK-5172 for Chronic Hepatitis C Virus Genotype 1 Infection at the International Liver Congress™ to Home Bancorp Announces 2013 First Quarter Results
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity